Pending FDA clearance of the IND application, Neurizon said it anticipated Massachusetts General Hospital filing a protocol ...

(ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce the filing of an Investigational New Drug ...

Tonix Pharmaceuticals was the most active symbol on Stocktwits before the bell on Wednesday as shares of the clinical-stage ...

KalVista has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of ...

Lupin is one of the first companies to receive approval for this formulation originally developed by Gilead Sciences, making ...

LONDON - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the ...

The global market for Artificial Intelligence For Drug Development and Discovery Market has witnessed rapid growth, escalating from a valuation of $520 million in 2019 to a projected $4,815 million by ...

- Cholesterol Efflux Mediator™ VAR 200 designed to mediate removal of renal lipids and cholesterol that lead to kidney damage ...

Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas ...

The majority of Teva's business lies in generic and off-patent branded drugs and faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

SandboxAQ has secured over $300 million in its latest funding round, catapulting its valuation to an impressive $5.3 billion.

Mayor Brandon Scott released a draft of the city's plan to address the opioid crisis Wednesday, in keeping with an executive ...